Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115:209–18.

PubMed  PubMed Central  CAS  Google Scholar 

Friedman SL. Liver fibrosis – from bench to bedside. J Hepatol. 2003;38:38–53.

Google Scholar 

How Many People Have Liver Disease? [Internet]. 2022 [cited 2023 Dec 11]. Available from: https://liverfoundation.org/about-your-liver/facts-about-liver-disease/how-many-people-have-liver-disease/.

Elpek GÖ. Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: An update. World J Gastroenterol. 2014;20:7260–76.

PubMed  PubMed Central  Google Scholar 

Zhang C-Y, Yuan W-G, He P, Lei J-H, Wang C-X. Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets. World J Gastroenterol. 2016;22:10512–22.

PubMed  PubMed Central  CAS  Google Scholar 

Gressner AM, Weiskirchen R, Breitkopf K, Dooley S. Roles of TGF-beta in hepatic fibrosis. Front Biosci. 2002;7:d793–807.

PubMed  CAS  Google Scholar 

Naito M, Hasegawa G, Ebe Y, Yamamoto T. Differentiation and function of Kupffer cells. Med Electron Microsc. 2004;37:16–28.

PubMed  CAS  Google Scholar 

Kamada Y, Tamura S, Kiso S, Matsumoto H, Saji Y, Yoshida Y, et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology. 2003;125:1796–807.

PubMed  CAS  Google Scholar 

Arriazu E, Ruiz de Galarreta M, Cubero FJ, Varela-Rey M, Pérez de Obanos MP, Leung TM, et al. Extracellular matrix and liver disease. Antioxid Redox Signal. 2014;21:1078–97.

PubMed  PubMed Central  CAS  Google Scholar 

Acharya P, Chouhan K, Weiskirchen S, Weiskirchen R. Cellular Mechanisms of Liver Fibrosis. Front Pharmacol. 2021;12:671640.

PubMed  PubMed Central  CAS  Google Scholar 

Dewidar B, Meyer C, Dooley S, Meindl-Beinker AN. TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis-Updated 2019. Cells. 2019;8:1419.

PubMed  PubMed Central  CAS  Google Scholar 

McQuitty CE, Williams R, Chokshi S, Urbani L. Immunomodulatory Role of the Extracellular Matrix Within the Liver Disease Microenvironment. Front Immunol. 2020;11:574276.

PubMed  PubMed Central  CAS  Google Scholar 

Dominguez M, Miquel R, Colmenero J, Moreno M, García-Pagán J, Bosch J, et al. Hepatic Expression of CXC Chemokines Predicts Portal Hypertension and Survival in Patients With Alcoholic Hepatitis. Gastroenterology. 2009;136:1639–50.

PubMed  CAS  Google Scholar 

Karin D, Koyama Y, Brenner D, Kisseleva T. The characteristics of activated portal fibroblasts/myofibroblasts in liver fibrosis. Differentiation. 2016;92:84–92.

PubMed  PubMed Central  CAS  Google Scholar 

Arthur MJP. Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. Am J Physiol Gastroint Liver Physiol. 2000;279:G245-9.

CAS  Google Scholar 

Bataller R, Gäbele E, Schoonhoven R, Morris T, Lehnert M, Yang L, et al. Prolonged infusion of angiotensin II into normal rats induces stellate cell activation and proinflammatory events in liver. Am J Physiol Gastrointest Liver Physiol. 2003;285:642–51.

Google Scholar 

Sharma A, Nagalli S. Chronic Liver Disease. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 Dec 12]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK554597/.

Pinto RB, Schneider ACR, da Silveira TR. Cirrhosis in children and adolescents: An overview. World J Hepatol. 2015;7:392–405.

PubMed  PubMed Central  Google Scholar 

Fibrosis: Development [Internet]. American Liver Foundation. 2022 [cited 2023 Dec 12]. Available from: https://liverfoundation.org/about-your-liver/how-liver-diseases-progress/fibrosis-scarring/.

Zhu Z, Chen Y, Qin X, Liu S, Wang J, Ren H. Multidimensional landscape of non-alcoholic fatty liver disease-related disease spectrum uncovered by big omics data: Profiling evidence and new perspectives. Smart Medicine. 2023;2:e20220029.

PubMed  PubMed Central  Google Scholar 

Chiang DJ, Pritchard MT, Nagy LE. Obesity, diabetes mellitus, and liver fibrosis. Am J Physiol Gastrointest Liver Physiol. 2011;300:G697-702.

PubMed  PubMed Central  CAS  Google Scholar 

van der Windt DJ, Sud V, Zhang H, Tsung A, Huang H. The Effects of Physical Exercise on Fatty Liver Disease. Gene Expr. 2018;18:89–101.

PubMed  PubMed Central  Google Scholar 

Osna NA, Donohue TM, Kharbanda KK. Alcoholic Liver Disease: Pathogenesis and Current Management. Alcohol Res. 2017;38:147–61.

PubMed  PubMed Central  Google Scholar 

Brunt EM. Pathology of fatty liver disease. Mod Pathol. 2007;20:S40–8.

PubMed  CAS  Google Scholar 

Patel R, Mueller M. Alcoholic Liver Disease. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 Dec 12]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK546632/.

Song C, Chen H, Yu B, Zhang L, Wang J, Feng C, et al. Magnetic Fields Affect Alcoholic Liver Disease by Liver Cell Oxidative Stress and Proliferation Regulation. Research. 2023;6:0097.

PubMed  PubMed Central  CAS  Google Scholar 

Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70:151–71.

PubMed  Google Scholar 

Ma X. Liver Fibrogenesis in Non-Alcoholic Steatohepatitis. Front Physiol [Internet]. 2012 [cited 2023 Dec 13];3. Available from: https://doi.org/10.3389/fphys.2012.00248.

Carpino G, Morini S, Ginanni Corradini S, Franchitto A, Merli M, Siciliano M, et al. Alpha-SMA expression in hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver transplantation. Dig Liver Dis. 2005;37:349–56.

PubMed  CAS  Google Scholar 

Souza-Mello V. Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease. World J Hepatol. 2015;7:1012–9.

PubMed  PubMed Central  Google Scholar 

Giby VG, Ajith TA. Role of adipokines and peroxisome proliferator-activated receptors in nonalcoholic fatty liver disease. World J Hepatol. 2014;6:570–9.

PubMed  PubMed Central  Google Scholar 

Seki E, Brenner DA. Recent advancement of molecular mechanisms of liver fibrosis. J Hepatobiliary Pancreat Sci. 2015;22:512–8.

PubMed  PubMed Central  Google Scholar 

Chen R-J, Wu H-H, Wang Y-J. Strategies to prevent and reverse liver fibrosis in humans and laboratory animals. Arch Toxicol. 2015;89:1727–50.

PubMed  CAS  Google Scholar 

El-Serag HB. Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma. Gastroenterology. 2012;142:1264-1273.e1.

PubMed  Google Scholar 

Tornesello ML, Buonaguro L, Izzo F, Buonaguro FM. Molecular alterations in hepatocellular carcinoma associated with hepatitis B and hepatitis C infections. Oncotarget. 2016;7:25087–102.

PubMed  PubMed Central  Google Scholar 

Stanhope KL, Schwarz JM, Keim NL, Griffen SC, Bremer AA, Graham JL, et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest. 2009;119:1322–34.

PubMed  PubMed Central  CAS  Google Scholar 

Jang C, Hui S, Lu W, Cowan AJ, Morscher RJ, Lee G, et al. The Small Intestine Converts Dietary Fructose into Glucose and Organic Acids. Cell Metab. 2018;27:351-361.e3.

PubMed  PubMed Central  CAS  Google Scholar 

Mazzanti R, Arena U, Tassi R. Hepatocellular carcinoma: Where are we? World J Exp Med. 2016;6:21–36.

PubMed  PubMed Central  Google Scholar 

Machado MV, Diehl AM. Pathogenesis of Nonalcoholic Steatohepatitis. Gastroenterology. 2016;150:1769–77.

PubMed  CAS  Google Scholar 

Kim JY, Garcia-Carbonell R, Yamachika S, Zhao P, Dhar D, Loomba R, et al. ER Stress Drives Lipogenesis and Steatohepatitis via Caspase-2 Activation of S1P. Cell. 2018;175:133-145.e15.

PubMed  PubMed Central  CAS  Google Scholar 

Maricic I, Marrero I, Eguchi A, Nakamura R, Johnson CD, Dasgupta S, et al. Differential Activation of Hepatic Invariant NKT Cell Subsets Plays a Key Role in Progression of Nonalcoholic Steatohepatitis. J Immunol. 2018;201:3017–35.

PubMed